5q chromosome deletion [del(5q)] probe, EGR1/D5S630 5P15(D5S630)/5q31.2 (EGR1) (CE-IVD)
Catalog No : FP-011-4
513.00€
0.00€
Shipping cost plus VAT not included , delivery in 7-14 business days
Product name | 5q chromosome deletion [del(5q)] probe, EGR1/D5S630 5P15(D5S630)/5q31.2 (EGR1) (CE-IVD) | ||
---|---|---|---|
Catalog No | FP-011-4 | ||
Supplier’s Catalog No | FP-011-4 | ||
Supplier | Wuhan Healthcare Biotech | ||
Source antigen | 5q | ||
Reactivity | 5q | ||
Cross reactivity | None | ||
Applications | Fluorescence In Situ Hybridization (FISH) | ||
Molecular weight | N/A |
Storage | -20°C | ||
---|---|---|---|
Other names | |||
Grade | Molecular diagnostic grade | ||
Purity | N/A | ||
Form | Liquid | ||
Reactivity life | 12 months when stored properly according to instructions | ||
Note | For Professional In Vitro diagnostics | ||
Description | Among the common chromosomal abnormalities in MDS patients, some chromosomal abnormalities have specific diagnostic value. Some patients with simple +8, 20q- or Y- are effective in immunosuppressive therapy, karyotyping is also of great value in the classification, treatment and prognosis of MDS, such as single Y-, 5q- or 20q-MDS Patients had a better prognosis, and patients with complex chromosomal abnormalities (≥3 abnormalities) or chromosome 7 abnormalities had a poor prognosis, and other abnormal patients had a moderate prognosis. NCCN and the “Chinese Expert Consensus for the Diagnosis and Treatment of Myelodysplastic Syndrome (2014 Edition)” recommend that all patients suspected of having MDS should have a chromosomal test, and fluorescent in situ hybridization probes (commonly abnormal sets of probes) are recommended. Abnormalities are important for the diagnosis, treatment, and prognosis of MDS. |
© 2020 Imugex All Rights Reserved